1,984
Views
51
CrossRef citations to date
0
Altmetric
Editorial

Freeing vaccine adjuvants from dangerous immunological dogma

Pages 7-10 | Published online: 09 Jan 2014
 

Financial & competing interests disclosure

This publication was supported by funds provided by Grant No. 5U01AI061142-02 from the National Institutes of Health, National Institute of Allergy and Infectious Diseases. Its contents are solely the responsibility of the author and do not necessarily represent the official views of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. The author performs consultancy work for Vaxine Pty Ltd, the company developing Advax and other adjuvants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.